Related Experiment Video
Updated: Jun 10, 2026

Noninvasive Electrocardiography in the Perinatal Mouse
Published on: June 12, 2020
Update on peripartum cardiomyopathy
Meredith O Cruz1, Joan Briller, Judith U Hibbard
1Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Illinois at Chicago, 840 South Wood Street, M/C 808, Chicago, IL 60612, USA. mcruz9@uic.edu
Insights
Peripartum cardiomyopathy (PPCM) is a heart condition in women near childbirth with unknown causes. Further research and an international registry are needed to improve diagnosis, treatment, and outcomes for PPCM patients.
Area of Science:
- Cardiology
- Maternal Health
- Heart Failure
Background:
- Peripartum cardiomyopathy (PPCM) is a rare form of heart failure.',
- Its exact cause remains unknown despite various postulated mechanisms.
- PPCM presents a diagnostic challenge, often being a diagnosis of exclusion.
Purpose of the Study:
- To review the current understanding of peripartum cardiomyopathy (PPCM).
- To discuss PPCM's pathogenesis, risk factors, diagnosis, and management.
- To highlight the need for further research and improved treatment strategies.
Main Methods:
- Literature review and discussion of existing data on PPCM.
- Analysis of diagnostic criteria and current treatment approaches.
- Exploration of prognostic factors and the potential of novel therapies.
Main Results:
- PPCM pathogenesis is not fully understood, with multiple contributing factors.
- Clinical presentation lacks specificity, complicating early diagnosis.
- Treatment is primarily supportive, with prognosis linked to cardiac function recovery.
Conclusions:
- Randomized controlled trials, particularly for therapies like bromocriptine, are essential.
- Establishing an international registry is crucial for better defining and treating PPCM.
- Improved understanding and therapeutic strategies are needed to reduce PPCM morbidity and mortality.
Abstract:
Although multiple mechanisms have been postulated, peripartum cardiomyopathy (PPCM) continues to be a cardiomyopathy of unknown cause. Multiple risk factors exist and the clinical presentation does not allow differentiation among potential causes. Although specific diagnostic criteria exist, PPCM remains a diagnosis of exclusion. Treatment modalities are dictated by the clinical state of the patient, and prognosis is dependent on recovery of function. Randomized controlled trials of novel therapies, such as bromocriptine, are needed to establish better treatment regimens to decrease morbidity and mortality. The creation of an international registry will be an important step to better define and treat PPCM. This article discusses the pathogenesis, risk factors, diagnosis, management, and prognosis of this condition.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VI: Nursing Management

